Can immunotherapy outperform chemo after stomach cancer surgery?
NCT ID NCT05468138
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This trial is testing whether giving a PD-1 immunotherapy drug after surgery can help people with a specific type of stomach cancer (MSI-H) live longer without the cancer coming back. Participants who had surgery to remove their stomach cancer will be randomly assigned to receive either standard chemotherapy, the immunotherapy drug, or just follow-up observation. The goal is to see if immunotherapy offers a better chance of staying cancer-free for three years compared to the other options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PD-1 monoclonal antibody immunotherapy (compared to standard chemotherapy or observation)
- What this could lead to
- If successful, this could establish immunotherapy as a better post-surgery option for MSI-H gastric cancer patients, potentially improving survival and reducing recurrence.
- What could go wrong
- This is a small phase II trial, so results may not be conclusive. Immunotherapy can cause immune-related side effects, and it's unclear if it will outperform standard chemo or observation in this setting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADJUVANT THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dazhi Xu
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can surgery for stomach or esophageal cancer cloud the mind?